Antitumor Immune Activity $ Safety of a Novel PD-1 Vaccine Alone & in Combination With 2 Chimeric HER-2 Peptide Vaccine in Syngeneic Balb/C & C57Bl/6 Models & in Canine and Non-Human Primates

Speaker
  • Professor of Medicine in Department of Ob/Gyn at the OSU Wexner Medical Center and the James Comprehensive Cancer Center, The Ohio State University
    Biography
      Kaumaya is Professor of Medicine in Department of Ob/Gyn at the OSU Wexner Medical Center and the James Comprehensive Cancer Center. Dr Kaumaya is internationally recognized as an expert in the fields of vaccine research with emphasis on peptide vaccines for cancer, viral diseases as well as peptide therapy for autoimmune diseases. He conducts research in the areas of tumor immunology, mechanisms of tumor cell-immune cell interactions, and immune mechanisms. The laboratory functions as an integrated translational research program with the goal of designing and developing new immunotherapies and immunologic strategies for cancer treatment and prevention. He is an inventor on several issued and pending patents for Peptide Vaccines and Therapeutic Technologies. He has lectured worldwide and has published over 130 peer-reviewed articles in major scientific journals Dr. Kaumaya is an elected fellow of the American Association for the Advancement of Science (AAAS), and he was elected as the treasurer of the American Peptide Society since 2009. Dr Kaumaya has conducted a first man/woman NCI funded and FDA approved Phase 1 Trial in Cancer Patients (Stage 4) with solid tumors in several indications (Breast, Ovarian, GIST) at the OSU James Cancer Hospital has recently been completed successfully

    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    JUL 22, 2020 10:00 AM PDT
    C.E. CREDITS
    JUL 22, 2020 10:00 AM PDT
    DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 04, 2020 11:00 AM PST
    C.E. CREDITS
    NOV 04, 2020 11:00 AM PST
    DATE: November 4th, 2020 TIME: 11:00am PST As cell therapies become more complex, the need for robust analytical tools to characterize such products as they enter the clinic has increased in...

    Antitumor Immune Activity $ Safety of a Novel PD-1 Vaccine Alone & in Combination With 2 Chimeric HER-2 Peptide Vaccine in Syngeneic Balb/C & C57Bl/6 Models & in Canine and Non-Human Primates


    No demographic data is available yet for this event.


    Show Resources
    Loading Comments...
    Show Resources